$ELVN
Enliven Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024126332 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.810M $4.640M
YoY Change 25.22% -0.19%
% of Gross Profit
Research & Development $21.26M $19.61M
YoY Change 8.43% 10672.53%
% of Gross Profit
Depreciation & Amortization $80.00K $79.00K
YoY Change 1.27% -24.04%
% of Gross Profit
Operating Expenses $27.07M $24.25M
YoY Change 11.63% 401.93%
Operating Profit -$27.07M -$24.25M
YoY Change 11.63% 401.93%
Interest Expense $3.839M $3.492M
YoY Change 9.94% 1342.98%
% of Operating Profit
Other Income/Expense, Net $3.912M $3.479M
YoY Change 12.45% 1467.12%
Pretax Income -$23.16M -$20.77M
YoY Change 11.49% 350.64%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.16M -$20.77M
YoY Change 11.49% 350.62%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$0.51
Diluted Earnings Per Share -$0.48 -$0.51
COMMON SHARES
Basic Shares Outstanding 48.86M 47.24M 41.15M
Diluted Shares Outstanding 48.27M 41.03M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.8M $263.5M
YoY Change 10.75% 368.0%
Cash & Equivalents $124.1M $100.6M $73.85M
Short-Term Investments $191.2M $189.6M
Other Short-Term Assets $5.163M $5.100M
YoY Change 1.24% 82.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $318.1M $297.0M $268.6M
YoY Change 19.53% 10.57% 354.46%
LONG-TERM ASSETS
Property, Plant & Equipment $458.0K $549.0K $806.0K
YoY Change -56.87% -31.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.175M $7.240M $3.614M
YoY Change 54.17% 100.33%
Total Long-Term Assets $7.633M $8.433M $5.435M
YoY Change 33.54% 55.16%
TOTAL ASSETS
Total Short-Term Assets $318.1M $297.0M $268.6M
Total Long-Term Assets $7.633M $8.433M $5.435M
Total Assets $325.8M $305.4M $274.0M
YoY Change 19.82% 11.45% 363.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.342M $1.019M $1.493M
YoY Change 152.26% -31.75% 94.65%
Accrued Expenses $16.01M $10.60M
YoY Change 51.02% 908.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.92M $17.03M $12.08M
YoY Change -38.54% 40.96% 564.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $214.0K
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $214.0K
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.92M $17.03M $12.08M
Total Long-Term Liabilities $0.00 $0.00 $214.0K
Total Liabilities $15.92M $17.03M $12.29M
YoY Change -38.7% 38.51% 576.18%
SHAREHOLDERS EQUITY
Retained Earnings -$243.5M -$220.3M -$135.1M
YoY Change 57.71% 63.06% -24.19%
Common Stock $49.00K $47.00K $41.00K
YoY Change 19.51% 14.63% 51.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $309.8M $288.4M $261.7M
YoY Change
Total Liabilities & Shareholders Equity $325.8M $305.4M $274.0M
YoY Change 19.82% 11.45% 363.66%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$23.16M -$20.77M
YoY Change 11.49% 350.62%
Depreciation, Depletion And Amortization $80.00K $79.00K
YoY Change 1.27% -24.04%
Cash From Operating Activities -$12.19M -$15.90M
YoY Change -23.31% 278.48%
INVESTING ACTIVITIES
Capital Expenditures $22.00K $20.00K
YoY Change 10.0% -195.24%
Acquisitions
YoY Change
Other Investing Activities $14.85M -$35.53M
YoY Change -141.79% -253.78%
Cash From Investing Activities $14.83M -$35.55M
YoY Change -141.7% -254.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.117M -420.0K
YoY Change -365.95%
NET CHANGE
Cash From Operating Activities -12.19M -15.90M
Cash From Investing Activities 14.83M -35.55M
Cash From Financing Activities 1.117M -420.0K
Net Change In Cash 3.750M -51.87M
YoY Change -107.23% -374.69%
FREE CASH FLOW
Cash From Operating Activities -$12.19M -$15.90M
Capital Expenditures $22.00K $20.00K
Free Cash Flow -$12.21M -$15.92M
YoY Change -23.27% 280.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001672619
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
elvn Lease Commencement Date
LeaseCommencementDate
2022-07-31
CY2024Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://www.enliventherapeutics.com/20240930#AccruedExpensesAndOtherCurrentLiabilities
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39247
dei Entity Registrant Name
EntityRegistrantName
ENLIVEN THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1523849
dei Entity Address Address Line1
EntityAddressAddressLine1
6200 Lookout Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
647-8519
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ELVN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48859166
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100621000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100141000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
191213000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
153007000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5109000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2949000
CY2024Q3 elvn Contingent Value Right Asset
ContingentValueRightAsset
0
CY2023Q4 elvn Contingent Value Right Asset
ContingentValueRightAsset
10000000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
296997000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
266151000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
549000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
742000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
81000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
320000
CY2024Q3 elvn Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
563000
CY2023Q4 elvn Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
563000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7240000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4091000
CY2024Q3 us-gaap Assets
Assets
305430000
CY2023Q4 us-gaap Assets
Assets
271867000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1019000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
532000
CY2024Q3 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16008000
CY2023Q4 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15362000
CY2024Q3 elvn Contingent Value Right Liability
ContingentValueRightLiability
0
CY2023Q4 elvn Contingent Value Right Liability
ContingentValueRightLiability
10000000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17027000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25894000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
67000
CY2024Q3 us-gaap Liabilities
Liabilities
17027000
CY2023Q4 us-gaap Liabilities
Liabilities
25961000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47254280
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47254280
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41292027
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41292027
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
47000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
508406000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
400172000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
242000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
141000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220292000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154448000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
288403000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
245906000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305430000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
271867000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21258000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19606000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60054000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46669000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5810000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4642000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17604000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14131000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
27068000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
24248000
us-gaap Operating Expenses
OperatingExpenses
77658000
us-gaap Operating Expenses
OperatingExpenses
60800000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27068000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24248000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77658000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60800000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3839000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3492000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11175000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8599000
CY2024Q3 elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
73000
CY2023Q3 elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
0
elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
873000
elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
232000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3912000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3479000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11814000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8586000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-23156000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20769000
us-gaap Net Income Loss
NetIncomeLoss
-65844000
us-gaap Net Income Loss
NetIncomeLoss
-52214000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
381000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-36000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
101000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-147000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22775000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20805000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65743000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52361000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48267458
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48267458
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41030874
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41030874
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46137170
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46137170
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33665067
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33665067
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-76825000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
CY2023Q1 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
73000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149749000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4955000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
159544000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
80241000
CY2023Q1 elvn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
9044000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2262000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14724000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
291416000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
141000
CY2023Q2 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
74000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4195000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16721000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-111000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
278994000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84000
CY2023Q3 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
74000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3401000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20769000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-36000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
261748000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
245906000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
320000
CY2024Q1 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
73000
CY2024Q1 elvn Payments Of Stock And Warrants Issuance Costs
PaymentsOfStockAndWarrantsIssuanceCosts
170000
CY2024Q1 elvn Issuance Of Common Stock Value And Prefunded Warrants In Private Placement Net Of Issuance Costs
IssuanceOfCommonStockValueAndPrefundedWarrantsInPrivatePlacementNetOfIssuanceCosts
89830000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4515000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-22738000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-194000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
317712000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1859000
CY2024Q2 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
68000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
320000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
135000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5144000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-19950000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-86000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
304932000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1004000
CY2024Q3 elvn Vesting Of Restricted Stock And Stock Options
VestingOfRestrictedStockAndStockOptions
66000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5176000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-23156000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
381000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
288403000
us-gaap Net Income Loss
NetIncomeLoss
-65844000
us-gaap Net Income Loss
NetIncomeLoss
-52214000
us-gaap Depreciation
Depreciation
237000
us-gaap Depreciation
Depreciation
219000
us-gaap Share Based Compensation
ShareBasedCompensation
14835000
us-gaap Share Based Compensation
ShareBasedCompensation
9858000
elvn Non Cash Lease Expense
NonCashLeaseExpense
239000
elvn Non Cash Lease Expense
NonCashLeaseExpense
228000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
552000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2815000
elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
873000
elvn Changes In Fair Value Of Contingent Value Right Liability
ChangesInFairValueOfContingentValueRightLiability
0
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5304000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5425000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-250000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-231000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
487000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1289000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1036000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2882000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55989000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48787000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
196672000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
40000000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
234225000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
226963000
elvn Proceeds From Receipt Of Contingent Value Right Milestone
ProceedsFromReceiptOfContingentValueRightMilestone
10000000
elvn Proceeds From Receipt Of Contingent Value Right Milestone
ProceedsFromReceiptOfContingentValueRightMilestone
0
elvn Payments Made Under Contingent Value Rights Agreement
PaymentsMadeUnderContingentValueRightsAgreement
9127000
elvn Payments Made Under Contingent Value Rights Agreement
PaymentsMadeUnderContingentValueRightsAgreement
0
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
44000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
135000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36724000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-187098000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3178000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
309000
elvn Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
320000
elvn Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
0
elvn Proceeds From Issuance Of Common Stock And Pre Funded Warrants In The Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInThePrivatePlacementNetOfIssuanceCosts
89695000
elvn Proceeds From Issuance Of Common Stock And Pre Funded Warrants In The Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInThePrivatePlacementNetOfIssuanceCosts
0
elvn Payment Of Deferred Offering Costs Related To The Sales Agreement
PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement
0
elvn Payment Of Deferred Offering Costs Related To The Sales Agreement
PaymentOfDeferredOfferingCostsRelatedToTheSalesAgreement
563000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161365000
elvn Proceeds From Cash Acquired In Connection With Reverse Recapitalization
ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization
0
elvn Proceeds From Cash Acquired In Connection With Reverse Recapitalization
ProceedsFromCashAcquiredInConnectionWithReverseRecapitalization
81821000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
8736000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93193000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234196000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
480000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1689000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100195000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75590000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100675000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73901000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100621000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73847000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
54000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
54000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100675000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73901000
us-gaap Income Taxes Paid
IncomeTaxesPaid
232000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
149749000
elvn Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets
ReceivablesFromStockOptionExercisesIncludedInPrepaidExpensesAndOtherCurrentAssets
5000
elvn Receivables From Stock Option Exercises Included In Prepaid Expenses And Other Current Assets
ReceivablesFromStockOptionExercisesIncludedInPrepaidExpensesAndOtherCurrentAssets
56000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-12
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-4
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41011501
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41011501
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 elvn Majority Number Of Initial Members Of Board Of Directors
MajorityNumberOfInitialMembersOfBoardOfDirectors
8
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 elvn Contigent Value Rights For Each Outstanding Shares
ContigentValueRightsForEachOutstandingShares
one
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
164500000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220300000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
291800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.574%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to stock-based compensation and accrued research and development expenses. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. Actual results may differ from those estimates or assumptions.</span></p>
elvn Restricted Cash Collateral Of Sublease
RestrictedCashCollateralOfSublease
54000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
54000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.574%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities, as well as restricted cash. The Company maintains deposits in U.S. federally insured financial institutions in excess of federally insured limits. The Company has established guidelines regarding approved investments, credit quality, diversification, liquidity and maturities of investments, which are designed to maintain safety and liquidity. Although management currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. As of September 30, 2024</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, the Company has not experienced any losses in its accounts and believes it is not exposed to significant credit risk on its cash balances.</span></p>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
81821000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
1044000
CY2023Q1 elvn Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities
2624000
CY2023Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
80241000
CY2023Q1 elvn Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
9000000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000000
CY2023Q1 elvn Fair Value Assessment Of Payments Under Contingent Value Rights Agreement
FairValueAssessmentOfPaymentsUnderContingentValueRightsAgreement
0
CY2024Q2 elvn Payments Received Under Contingent Value Rights Agreement
PaymentsReceivedUnderContingentValueRightsAgreement
10000000
elvn Terms Of Cvr Agreement
TermsOfCvrAgreement
Pursuant to the terms of the CVR Agreement, the Company has 45 days from the end of the calendar quarter in which funds are received to deliver the milestone proceeds, net of permitted deductions, to the rights agent for distribution to the CVR holders.
CY2024Q3 elvn Permitted Deductions Under Contingent Value Rights Agreement
PermittedDeductionsUnderContingentValueRightsAgreement
900000
CY2024Q3 elvn Contingent Value Rights Agreement Liability
ContingentValueRightsAgreementLiability
9100000
CY2024Q3 elvn Payments Made Under Contingent Value Rights Agreement
PaymentsMadeUnderContingentValueRightsAgreement
9100000
CY2023Q4 elvn Contingent Value Rights Agreement Liability
ContingentValueRightsAgreementLiability
10000000
elvn Change In Fair Value Upon Remeasurement
ChangeInFairValueUponRemeasurement
-873000
elvn Payments Made Under Contingent Value Rights Agreement
PaymentsMadeUnderContingentValueRightsAgreement
9127000
CY2024Q3 elvn Contingent Value Rights Agreement Liability
ContingentValueRightsAgreementLiability
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
190971000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
243000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
191213000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152866000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
147000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
153007000
CY2020Q2 elvn Area Of Leased Office And Laboratory Space
AreaOfLeasedOfficeAndLaboratorySpace
6782
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-30
CY2021Q1 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
2495
CY2021Q1 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
9277
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
12000
CY2022Q2 elvn Lessee Operating Lease Extended Date
LesseeOperatingLeaseExtendedDate
2024-12-31
CY2024Q3 elvn Area Of Leased Office Space
AreaOfLeasedOfficeSpace
18170
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
4
CY2024Q3 elvn Operating Lease Remaining Right Of Use Asset
OperatingLeaseRemainingRightOfUseAsset
100000
CY2024Q3 elvn Operating Remaining Lease Liability
OperatingRemainingLeaseLiability
100000
CY2023Q4 elvn Operating Lease Remaining Right Of Use Asset
OperatingLeaseRemainingRightOfUseAsset
300000
CY2023Q4 elvn Operating Remaining Lease Liability
OperatingRemainingLeaseLiability
300000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
81000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
81000
us-gaap Operating Lease Expense
OperatingLeaseExpense
244000
us-gaap Operating Lease Expense
OperatingLeaseExpense
244000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
85000
CY2024Q3 elvn Lessee Operating Lease Liability Payments Due After Year One
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
85000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
0
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
85000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1457000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1413000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
908000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
671000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
549000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
742000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
237000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
220000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3478000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3328000
CY2024Q3 elvn Accrued Research And Development Cost Current
AccruedResearchAndDevelopmentCostCurrent
11525000
CY2023Q4 elvn Accrued Research And Development Cost Current
AccruedResearchAndDevelopmentCostCurrent
10433000
CY2024Q3 elvn Lease Liability Current
LeaseLiabilityCurrent
85000
CY2023Q4 elvn Lease Liability Current
LeaseLiabilityCurrent
335000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
704000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
902000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
216000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
364000
CY2024Q3 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16008000
CY2023Q4 elvn Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
15362000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47254280
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47254280
CY2024Q3 elvn Common Stock Number Of Shares Subject To Repurchase
CommonStockNumberOfSharesSubjectToRepurchase
28236
CY2023Q4 elvn Common Stock Number Of Shares Subject To Repurchase
CommonStockNumberOfSharesSubjectToRepurchase
86153
CY2024Q3 elvn Common Stock Liability Related To Shares Subject To Repurchase
CommonStockLiabilityRelatedToSharesSubjectToRepurchase
100000
CY2023Q4 elvn Common Stock Liability Related To Shares Subject To Repurchase
CommonStockLiabilityRelatedToSharesSubjectToRepurchase
400000
CY2024Q3 elvn Number Of Vote By Common Stock Holders
NumberOfVoteByCommonStockHolders
1
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
34426351
CY2023Q1 elvn Business Acquisition Exchange Ratio
BusinessAcquisitionExchangeRatio
0.002951
CY2023Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18216847
CY2023Q1 elvn Pre Merger Financing Amount
PreMergerFinancingAmount
164500000
CY2023Q1 elvn Pre Merger Financing Shares Issued
PreMergerFinancingSharesIssued
12638636
elvn Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding
StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding
7449126
CY2023 elvn Stock Issued During Period Shares Upon Exercise Of Stock Options Outstanding
StockIssuedDuringPeriodSharesUponExerciseOfStockOptionsOutstanding
5817339
CY2024Q3 elvn Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
92317
CY2023Q4 elvn Issuance Of Common Stock Upon Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
78505
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4062571
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1574426
CY2024Q3 elvn Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants
IssuanceOfCommonStockUponExerciseOfPreFundedWarrants
1071505
CY2023Q4 elvn Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants
IssuanceOfCommonStockUponExerciseOfPreFundedWarrants
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13453608
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7873027
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5817339
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2322486
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.49
elvn Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriod
617557
elvn Share Based Compensation Arrangements By Share Based Payment Award Options Exercised And Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedAndVestedInPeriodWeightedAverageExercisePrice
5.49
elvn Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelledInPeriod
73142
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
52.7
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7449126
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.15
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
46400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5176000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3401000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14835000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9858000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-23156000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20769000
us-gaap Net Income Loss
NetIncomeLoss
-65844000
us-gaap Net Income Loss
NetIncomeLoss
-52214000
CY2024Q3 elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
48302633
CY2023Q3 elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
41161094
elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
46190019
elvn Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
33840688
CY2024Q3 elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
35080
CY2023Q3 elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
109068
elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
50841
elvn Weighted Average Unvested Common Stock Issued Upon Early Exercise Of Common Stock Options
WeightedAverageUnvestedCommonStockIssuedUponEarlyExerciseOfCommonStockOptions
129468
CY2024Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
95
CY2023Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
21152
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
2008
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
46153
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48267458
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48267458
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41030874
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41030874
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46137170
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46137170
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33665067
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33665067
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7554375
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5984366
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-126332-index-headers.html Edgar Link pending
0000950170-24-126332-index.html Edgar Link pending
0000950170-24-126332.txt Edgar Link pending
0000950170-24-126332-xbrl.zip Edgar Link pending
elvn-20240930.htm Edgar Link pending
elvn-20240930.xsd Edgar Link pending
elvn-ex31_1.htm Edgar Link pending
elvn-ex31_2.htm Edgar Link pending
elvn-ex32_1.htm Edgar Link pending
elvn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img252672916_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
elvn-20240930_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable